MedTrace Logo

Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation

NCT04833712 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-04-06

No results posted yet for this study

Summary

The study aims to investigate the short-term (3 months) and intermediate-term (12 months) safety and preliminary efficacy of stereotactic radiotherapy for pulmonary vein isolation to treat refractory atrial fibrillation.

Conditions

Interventions

RADIATION

Stereotactic Radioablation

Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • National and Kapodistrian University of Athens

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2021-08-30
Completion
2022-08-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833712 on ClinicalTrials.gov